×
About 6,205 results

ALLMedicine™ Vitiligo Center

Research & Reviews  1,978 results

Vitiligo: An immune disease and its emerging mesenchymal stem cell therapy paradigm.
https://doi.org/10.1016/j.trim.2022.101766
Transplant Immunology; Zhang M, Xia T et. al.

Dec 5th, 2022 - Melanocyte damage, innate immune response, adaptive immune response, and immune inflammatory microenvironment disorders are involved in the development of the immunological pathogenic mechanism of vitiligo. Mesenchymal stem cells are considered an...

Vitiligo treatment with coloured illustration by Turkish physician Şerefeddin Sabuncuoğ...
https://doi.org/10.1111/jdv.18773
Journal of the European Academy of Dermatology and Venere... Serarslan G

Dec 4th, 2022 - Vitiligo treatment with coloured illustration by Turkish physician Şerefeddin Sabuncuoğlu, in the 15th century.|2022|Serarslan G,|

Comparison of NB-UVB combination therapy regimens for vitiligo: A systematic review and...
https://doi.org/10.1111/jocd.15534
Journal of Cosmetic Dermatology; Zhu B, Liu C et. al.

Dec 2nd, 2022 - Vitiligo was an autoimmune disease and some guidelines for the management of vitiligo encouraged the use of NB-UVB combination therapies to enhance repigmentation. To compare the effectiveness of current NB-UVB combination regimen at the improveme...

Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepa...
https://doi.org/10.1007/s00296-022-05247-5
Rheumatology International; Zekić T, Benić MS

Dec 1st, 2022 - Nivolumab (NIVO) is a monoclonal antibody used to treat renal cell cancer. It is an anti-programmed death-1 (anti-PD-1) inhibitor, enhancing the tumor-targeted immune response of T lymphocytes, resulting in immune-mediated adverse events (AEs). We...

Orbital inflammatory pseudotumor revealing multi-organ immunoglobulin G4-related disease.
https://doi.org/10.1111/1756-185X.14521
International Journal of Rheumatic Diseases; Ben Salah R, Kammoun S et. al.

Nov 30th, 2022 - Relatively recently, the concept that immunoglobulin G4 (IgG4)-related disease is a distinct chronic inflammatory disorder rather than a subset of Sjögren's syndrome has been accepted. IgG4-related disease (IgG4-RD) is a fibro-inflammatory systemi...

see more →

Guidelines  1 results

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  205 results

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Oct 14th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05577637

Oct 13th, 2022 - Vitiligo is a skin disorder that causes substantial social and psychological distress due to multiple patches of depigmentation.Disease can target at any age, but it appears to affect various parts of body due to loss of melanin. Although the exac...

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05247489

Oct 10th, 2022 - The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% b...

Tregs CD25 CXCL9 in Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05569096

Oct 6th, 2022 - Vitiligo is an acquired and polygenic skin depigmenting disease characterized by bilateral, symmetrical depigmented patches over the entire body. Its pathogenesis is multifactorial; however, the exact mechanisms that integrate the individual genet...

Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05536856

Oct 3rd, 2022 - A novel approach for 5-Fluorouracil delivery based on a solid effervescent formulation is proposed . 5-Fluorouracil is water soluble (~50mg/ml) and therefore has been used for the development of novel topical formulations including nano and microp...

see more →

News  277 results

Lego Introduces First Character With Vitiligo
https://www.medscape.com/viewarticle/983548

Nov 7th, 2022 - The spotlight continues to shine on vitiligo as Lego has released the first-ever mini-character featuring the hallmark dark and light skin patches of the disease. The character appears with the customizable array of players to assemble for a table...

Ruxolitinib Repigments Many Vitiligo Affected Body Areas
https://www.medscape.com/viewarticle/981758

Oct 3rd, 2022 - Ruxolitinib (Opzelura) cream can help repigment the skin in many body areas affected with vitiligo, researchers reported at the European Academy of Dermatology and Venereology (EADV) 2022 Annual Meeting. Those difficult areas include the hands and...

Commentary: New Topical Approaches Hit the Spots (and the Itch) for AD, October 2022
https://www.mdedge.com/dermatology/article/258243/atopic-dermatitis/commentary-new-topical-approaches-hit-spots-and-itch-ad
Jonathan Silverberg, MD, PhD, MPH

Sep 27th, 2022 - Jonathan Silverberg, MD, PhD, MPH Over the past few months, I have commented on cutting-edge data supporting the use of multiple agents that were recently approved for the treatment of atopic dermatitis (AD), including injectable dupilumab and tra.

Relatlimab Plus Nivolumab Approved in Europe for Unresectable or Metastatic Melanoma with PD-L1 <1%
https://www.onclive.com/view/relatlimab-plus-nivolumab-approved-in-europe-for-unresectable-or-metastatic-melanoma-with-pd-l1-1-

Sep 17th, 2022 - The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab (Opdivo; Opdualag) for use in the frontline treatment of adult and adolescent patients aged 12 years of age and older with advanced or metastatic melanoma...

Linear Hypopigmentation on the Right Arm
https://www.mdedge.com/dermatology/article/257581/pigmentation-disorders/linear-hypopigmentation-right-arm
Kathryn Lee, BA, Yang Li, MD et. al.

Sep 6th, 2022 - The Diagnosis: Chemical Leukoderma A clinical diagnosis of chemical leukoderma was made. In our patient, the observed linear hypopigmentation likely resulted from the prior treatment for De Quervain tenosynovitis in which an intralesional corticos.

see more →

Patient Education  14 results see all →